HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.03921106v1 2/2/264    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deo, A. Articles by Cowper, S. E. Search for Related Content PubMed PubMed Citation Articles by Deo, A. Articles by Cowper, S. E. Related Collections Related Article

Nephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure

Aneet Deo^*, Mitchell Fogel^,, and Shawn E. Cowper

^* Department of Medicine and Division of Nephrology, St. Vincent’s Medical Center, Bridgeport, Connecticut; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York; and Departments of Dermatology and Pathology, Yale University School of Medicine, New Haven, Connecticut

Address correspondence to: Dr. Shawn E. Cowper, Department of Dermatology, Yale University School of Medicine, 15 York Street, LMP 5031, New Haven, CT 06520. Phone: 203-785-4094; Fax: 203-785-6869; E-mail: shawn.cowper{at}yale.edu

Nephrogenic systemic fibrosis (NSF) is a devastating complication of severe renal failure. Recent reports suggest that exposure to gadolinium-containing contrast agents (GCCA) is associated with the occurrence of NSF. The population of patients with ESRD in and around Bridgeport, CT, was studied during an 18-mo period. The incidence of NSF was 4.3 cases per 1000 patient-years. Each radiologic study using gadolinium presented a 2.4% risk for NSF. The association between gadolinium exposure and NSF was highly significant (P 0.001). It is concluded that GCCA exposure is a major risk factor for NSF in the ESRD population. Because of the significant morbidity and mortality with NSF, it is believed that gadolinium exposure should be avoided in patients with ESRD. In the event that exposure cannot be avoided, careful consideration of the potential consequences, including a thorough discussion of the risks and benefits of GCCA, is advised.

Related Article

Nephrogenic Systemic Fibrosis, Kidney Disease, and Gadolinium: Is There a Link?

Mark A. Perazella
Clin. J. Am. Soc. Nephrol. 2007 2: 200-202. [Full Text] [PDF]

This article has been cited by other articles:

				A. Kreuter, T. Gambichler, S. M. Weiner, and G. Schieren Limited Effects of UV-A1 Phototherapy in 3 Patients With Nephrogenic Systemic Fibrosis Arch Dermatol, November 1, 2008; 144(11): 1527 - 1529. [Full Text] [PDF]

				R. Agarwal, S. M. Brunelli, K. Williams, M. D. Mitchell, H. I. Feldman, and C. A. Umscheid Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis Nephrol. Dial. Transplant., October 24, 2008; (2008) gfn593v1. [Abstract] [Full Text] [PDF]

				J. C. Weinreb Which Study When? Is Gadolinium-enhanced MR Imaging Safer than Iodine-enhanced CT? Radiology, October 1, 2008; 249(1): 3 - 8. [Full Text] [PDF]

				F. G. Shellock and A. Spinazzi MRI Safety Update 2008: Part 1, MRI Contrast Agents and Nephrogenic Systemic Fibrosis Am. J. Roentgenol., October 1, 2008; 191(4): 1129 - 1139. [Abstract] [Full Text] [PDF]

				M. R. Prince, H. Zhang, M. Morris, J. L. MacGregor, M. E. Grossman, J. Silberzweig, R. L. DeLapaz, H. J. Lee, C. M. Magro, and A. M. Valeri Incidence of Nephrogenic Systemic Fibrosis at Two Large Medical Centers Radiology, September 1, 2008; 248(3): 807 - 816. [Abstract] [Full Text] [PDF]

				R. Habibi, M. S. Krishnam, D. G. Lohan, F. Barkhordarian, M. Jalili, R. S. Saleh, S. G. Ruehm, and J. P. Finn High-Spatial-Resolution Lower Extremity MR Angiography at 3.0 T: Contrast Agent Dose Comparison Study Radiology, August 1, 2008; 248(2): 680 - 692. [Abstract] [Full Text] [PDF]

				Y. Tsushima, A. Takahashi-Taketomi, and K. Endo Nephrogenic Systemic Fibrosis in Japan: Advisability of Keeping the Administered Dose as Low as Possible Radiology, June 1, 2008; 247(3): 915 - 916. [Full Text] [PDF]

				R. F. Reilly Risk for Nephrogenic Systemic Fibrosis with Gadoteridol (ProHance) in Patients Who Are on Long-Term Hemodialysis Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 747 - 751. [Abstract] [Full Text] [PDF]

				M. A. Perazella How Should Nephrologists Approach Gadolinium-based Contrast Imaging in Patients with Kidney Disease? Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 649 - 651. [Full Text] [PDF]

				N. ISSA, E. D. POGGIO, R. A. FATICA, R. PATEL, P. M. RUGGIERI, and R. J. HEYKA Nephrogenic systemic fibrosis and its association with gadolinium exposure during MRI Cleveland Clinic Journal of Medicine, February 1, 2008; 75(2): 95 - 111. [Abstract] [Full Text] [PDF]

				A. Kahana, M. J. Lucarelli, A. M. Grayev, J. J. Van Buren, C. N. Burkat, and L. R. Gentry Noninvasive Dynamic Magnetic Resonance Angiography With Time-Resolved Imaging of Contrast KineticS (TRICKS) in the Evaluation of Orbital Vascular Lesions Arch Ophthalmol, December 1, 2007; 125(12): 1635 - 1642. [Abstract] [Full Text] [PDF]